Health policy

Me-too drugs with limited benefits-the tale of regorafenib for HCC

Bishal Gyawali, Vinay Prasad

Research output: Contribution to journalShort survey

10 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)653-654
Number of pages2
JournalNature Reviews Clinical Oncology
Volume14
Issue number11
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Cite this

Health policy : Me-too drugs with limited benefits-the tale of regorafenib for HCC. / Gyawali, Bishal; Prasad, Vinay.

In: Nature Reviews Clinical Oncology, Vol. 14, No. 11, 01.11.2017, p. 653-654.

Research output: Contribution to journalShort survey

@article{17df9063329946268231f1180e0ee944,
title = "Health policy: Me-too drugs with limited benefits-the tale of regorafenib for HCC",
author = "Bishal Gyawali and Vinay Prasad",
year = "2017",
month = "11",
day = "1",
doi = "10.1038/nrclinonc.2017.100",
language = "English (US)",
volume = "14",
pages = "653--654",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Health policy

T2 - Me-too drugs with limited benefits-the tale of regorafenib for HCC

AU - Gyawali, Bishal

AU - Prasad, Vinay

PY - 2017/11/1

Y1 - 2017/11/1

UR - http://www.scopus.com/inward/record.url?scp=85030868808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030868808&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2017.100

DO - 10.1038/nrclinonc.2017.100

M3 - Short survey

VL - 14

SP - 653

EP - 654

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 11

ER -